FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy Pharmaceutical Investing
Merck’s KEYTRUDA Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial Pharmaceutical Investing
Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix Pharmaceutical Investing
VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage Pharmaceutical Investing
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP Pharmaceutical Investing
Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity Pharmaceutical Investing
